Search All Jobs

Showing 14 of 14 Jobs

Account Executive - Pathology Sales-Oncology Division

Full-Time

Salt Lake City, UT, USA

Account Executive - Pathology Sales-Oncology Division

Full-Time

Pittsburgh, PA, USA

Account Executive - Pathology Sales-Oncology Division

Full-Time

New York, NY, USA

Account Executive - Pathology Sales-Oncology Division

Full-Time

Atlanta, GA, USA

Account Executive - Pathology Sales-Oncology Division

Full-Time

Chicago, IL, USA

Senior Biopharma Translational Strategy & Applications Director

Full-Time

Remote in USA

Account Executive - Pathology Sales-Oncology Division

Full-Time

Boston, MA, USA

Account Executive - Pathology Sales-Oncology Division

Full-Time

Dallas, TX, USA

Scientist I

Full-Time

San Carlos, CA, USA

Account Executive - Pathology Sales-Oncology Division

Full-Time

New York, NY, USA

Account Executive - Pathology Sales-Oncology Division

Full-Time

Detroit, MI, USA

Account Executive - Pathology Sales-Oncology Division

Full-Time

Miami, FL, USA

Account Executive - Pathology Sales-Oncology Division

Full-Time

Kansas City, KS, USA

Account Executive - Pathology Sales-Oncology Division

Full-Time

Phoenix, AZ, USA

Full-Time

Account Executive

Pathology Sales-Oncology Division

Posted on 5/17/2025

Guardant Health

Guardant Health

1,001-5,000 employees

Develops blood tests for cancer diagnostics

No salary listed

Senior, Expert

Salt Lake City, UT, USA

Category
Genomics
Biology Lab & Research
Sales & Account Management
Biology & Biotech
Required Skills
Salesforce
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Guardant Health referral from your network.

đź’ˇ

Applications through a referral are 3x more likely to get an interview!

Requirements
  • 7+ years in account management in pathology sales, diagnostics, lab services, or oncology-related roles (highly prefer experience selling in diagnostics directly to Pathologists)
  • Deep knowledge of FFPE Tissue based NGS / CGP testing
  • Deep knowledge of pathology workflows, molecular diagnostics, or oncology therapeutic areas.
  • A customer-first mindset and the ability to influence clinical decision-makers with empathy and clarity.
  • Demonstrated track record of delivering results in a consultative sales environment.
  • Familiarity with pathology billing, reimbursement, and lab contracting a plus.
  • Proficiency with CRM tools (Salesforce preferred) and Microsoft Office Suite.
  • Ability to travel >50% within your territory.
Responsibilities
  • Drive overall 360 tissue volume in assigned / overlapping regions.
  • Promote the adoption of precision oncology diagnostics and the Guardant Health testing portfolio with the focus on driving 360 tissue.
  • Execute Laboratory Service Agreements and break down ordering barriers in accounts.
  • Negotiate pricing agreements based on a tied pricing schedule and facilitate escalation of pricing exceptions outside of guardrails.
  • Work with the KAD and KAM overlapping the region on higher level partnership agreements and contracts.
  • Present Guardant services and solutions to C-level executives in hospitals and pathology departments.
  • Target and close new business opportunities for tissue testing in pathology accounts in the community oncology setting and at academic cancer centers.
  • Manage and expand existing accounts to ensure client satisfaction and retention.
  • Collaborate with internal teams (medical, billing, operations) to resolve client issues.
  • Forecast sales and manage account pipelines via CRM.
  • Facilitate obtaining FFPE tissue processing agreements, where needed, and agreements for reimbursement of slide processing / cutting in place with the hospitals and or path labs.
Desired Qualifications
  • Advanced degree or clinical/lab background a plus.

Guardant Health specializes in blood-based tests that provide essential information for cancer treatment and management. Their products are designed to assist patients at various stages of cancer, from early detection to managing advanced disease. The company develops and sells diagnostic tests that utilize blood samples to detect, monitor, and guide treatment decisions for cancer patients. Their main product, Guardant360, is FDA-approved and widely used to help inform treatment choices for those with advanced cancer. Guardant Health is also working on expanding its offerings to include tests for early-stage cancer detection and monitoring for recurrence. By focusing on non-invasive and data-rich diagnostics, the company aims to enhance patient outcomes and lessen the overall impact of cancer.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnerships with Pfizer and ConcertAI enhance research and therapy development capabilities.
  • Growing demand for liquid biopsy tests supports Guardant Health's market expansion.
  • FDA approvals bolster credibility and adoption of Guardant Health's diagnostic solutions.

What critics are saying

  • Increased competition from companies like Natera may erode market share.
  • Dependency on key partnerships, like with Pfizer, poses revenue concentration risks.
  • Challenges in early-stage cancer detection expansion may delay revenue growth.

What makes Guardant Health unique

  • Guardant Health specializes in non-invasive, blood-based cancer diagnostics.
  • The company offers FDA-approved tests like Guardant360 for advanced cancer treatment decisions.
  • Guardant Health integrates AI and real-world data for precision oncology solutions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↓ -1%

2 year growth

↓ -1%
360Dx
Apr 24th, 2025
Guardant Health, Pfizer Partner to Use Liquid Biopsy to Aid Cancer Therapy Development

NEW YORK - Guardant Health said Thursday that it has entered a multiyear strategic collaboration with Pfizer, under which it will support the development and commercialization of cancer therapies using its Guardant Infinity liquid biopsy platform.

Asian Hospital & Healthcare Management
Jan 17th, 2025
Guardant Health and ConcertAI Partner to Launch Data-as-a-Service Platform Integrating Clinical and Tumour Profiling Data to Speed Up Cancer Therapy Research and Development

Guardant Health, a leading precision oncology company, has entered into a collaboration with ConcertAI, an oncology real-world evidence (RWD) data and AI technology company.

Hit Consultant
Jan 17th, 2025
Guardant Health And Concertai Partner To Unlock Cancer Insights With Multi-Modal Real-World Data

What You Should Know:– Guardant Health, a provider in precision oncology, and ConcertAI, a real-world evidence (RWE) and AI technology company in oncology, announced a strategic collaboration that will provide biopharmaceutical companies with access to a first-of-its-kind multi-modal real-world data (RWD) solution.– The partnership integrates comprehensive patient electronic medical record (EMR) data with genomic and epigenomic tumor profiling information, offering a deeper understanding of cancer biology and treatment response.Enhanced Cancer Research and DevelopmentCancer is a complex disease, and a patient’s response to treatment can be influenced by various factors, including specific genetic mutations, prior therapies, and the development of drug resistance. This new joint RWD solution provides critical clinical context to an extensive database of solid tumor cancer patients with multiple liquid biopsies. This allows biopharma researchers to:Better interpret disease biology: Gain a more comprehensive understanding of the underlying mechanisms driving cancer progression.Gain a more comprehensive understanding of the underlying mechanisms driving cancer progression. Identify drivers of tumor evolution: Pinpoint the specific genetic and epigenetic changes that contribute to tumor growth and spread.Pinpoint the specific genetic and epigenetic changes that contribute to tumor growth and spread. Understand resistance mechanisms: Uncover how tumors develop resistance to therapies, both intrinsically and over time.By leveraging this comprehensive dataset, combined with the analytics capabilities and AI SaaS solutions of both ConcertAI and Guardant Health, biopharmaceutical companies can gain a deeper understanding of cancer and develop more effective treatments.“Realizing the potential of precision medicine requires a comprehensive, multi-dimensional understanding of the tumor, the clinical environment and the patient’s response to therapy,” said Helmy Eltoukhy, Guardant Health co-CEO. “This partnership between Guardant and ConcertAI gives evidence and outcomes researchers access to extensive, robust data and AI-based modeling that can provide unprecedented insight into a patient’s cancer journey, including a tumor’s complex systemic interactions, to help them accelerate the development of much-needed cancer therapies

Guardant Health
Jan 2nd, 2025
Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

PALO ALTO, Calif.-(BUSINESS WIRE)- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.

HC Data
Dec 19th, 2024
COTA and Guardant Health Partner to Advance Precision Oncology with AI and Real-World Data

COTA Inc., a leader in real-world data (RWD) and analytics for oncology, has announced a new partnership with precision oncology company Guardant Health Inc. (Nasdaq: GH).